Abstract:Background: An increase in deaths has been perceived during the pandemic, which cannot be explained only by COVID-19. The actual number of deaths far exceeds the recorded data on deaths directly related to SARS-CoV-2 infection. Data from early and short-lived pandemic studies show a dramatic shift in cardiovascular mortality. Grounded in the post-pandemic era, macroscopic big data on cardiovascular mortality during the pandemic need to be further reviewed and studied, which is crucial for cardiovascular disease prevention and control. Methods: We retrieved and collected data associated with cardiovascular disease mortality from the National Vital Statistic System from the Center for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) platform based on the ICD-10 codes. We applied regression analysis to characterize overall cardiovascular disease mortality trends from 2010 to 2023 and built a time series model to predict mortality for 2020–2023 based on mortality data from 2010 to 2019 in order to affirm the existence of the excess deaths by evaluating observed vs. predicted mortality. We also conducted subgroup analyses by sex, age and race/ethnicity for the purpose of obtaining more specific sociodemographic information. Results: All-cause age-standardised mortality rates (ASMRs) for CVD dramatically increased between 2019 and 2021[annual percentage change (APC) 11.27%, p < 0.01], and then decreased in the following 2021–2023(APC: −7.0%, p < 0.01). Subgroup analyses found that the ASMR change was most pronounced in Alaska Indians/Native American people (APC: 16.5% in 2019–2021, −12.5% in 2021–2023, both p < 0.01), Hispanics (APC: 12.1% in 2019–2021, −12.2% in 2021–2023, both p < 0.05) and non-Hispanic Black people (APC:11.8% in 2019–2021, −10.3% in 2021–2023, both p < 0.01)whether during the increasing or declining phase. Similarly, the ASMR change was particularly dramatic for the 25–44 age group (APC:19.8% in 2019–2021, −15.4% in 2021–2023, both p < 0.01) and males (APC: 11.5% in 2019–2021, −7.6% in 2021–2023, both p < 0.01). By the end of 2023, the proportion of COVID-related excess death remained high among the elderly (22.4%), males (42.8%) and Alaska Indians/Native American people(39.7%). In addition, we did not find the presence of excess deaths in the young (25–44) and middle-aged cohort (45–64) in 2023, while excess deaths remained persistent in the elderly. Conclusions: All-cause ASMRs for CVD increased notably during the initial two years of the COVID-19 pandemic and then witnessed a decline in 2021–2023. The cohorts (the young, males and minorities) with the steepest rise in mortality decreased at the fastest rate instead. Previous initiatives to promote cardiovascular health were effective, but further research on cardiovascular healthcare for the elderly and racial disparities should be attached to priority considering the presence of sociodemographic differences in CVD death.

Excess psoriasis and psoriatic arthritis mortality during the COVID-19 pandemic in the United States: A nationwide population-based study from 2010 to 2021

Excess Risk for Acute Myocardial Infarction Mortality During the COVID-19 Pandemic

Excess Deaths from Alzheimer’s Disease and Parkinson’s Disease During the COVID-19 Pandemic in the USA

Age and urban–rural disparities in cutaneous melanoma mortality rates in the United States during the COVID‐19 pandemic

Impact of the COVID-19 pandemic on cardiovascular mortality and contrast analysis within subgroups

P076 Risk of psoriatic arthritis and uveitis among patients with psoriasis after COVID-19 infection: a nationwide cohort study

Enhanced impact of psoriasis severity on the treatment demands of patients during the COVID-19 pandemic: a cross-sectional study based on a national psoriasis registry in China

Coronavirus Disease 2019 and Psoriatic Arthritis: Features and Connections

Risk Factors for Mortality of Coronavirus Disease 2019 (COVID-19) Patients During the Early Outbreak of COVID-19: a Systematic Review and Meta-Analysis

Excess of Heart Failure-Related Deaths During the 2020 COVID-19 Pandemic in Unites States

Different COVID-19 outcomes among systemic rheumatic diseases: a nation-wide cohort study

Two years of Covid-19: Excess mortality by age, region, gender, and race/ethnicity in the United States during the Covid-19 pandemic, March 1, 2020, through February 28, 2022

COVID-19 and Sepsis-Related Excess Mortality in the US During the First Three Years: A National-Wide Time Series Study.

Chronic Obstructive Pulmonary Disease Mortality and Hospitalization during the COVID-19 Pandemic Compared with before the Pandemic: A Systematic Review and Meta-Analysis

Association of Outdoor Activity Restriction and Income Loss with Patient-Reported Outcomes of Psoriasis During the COVID-19 Pandemic: A Web-Based Survey.

Nationwide Cross-Sectional Analysis of Mortality Trends in Patients with Sarcoidosis and Non-Ischemic Cardiovascular Disease—The Impact of Gender, Ethnicity, Geographical Location, and COVID-19 Pandemic

Cause-Specific Excess Mortality in the US During the COVID-19 Pandemic

Impact of the COVID-19 Pandemic on Liver Disease-Related Mortality Rates in the United States.

Abstract 11754: Trends in Cardiovascular Mortality Before and During the COVID-19 Pandemic

Impact of COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease Healthcare Use, Exacerbations, and Mortality: A Population Study

Global Excess Mortality During COVID-19 Pandemic: A Systematic Review and Meta-Analysis